Medicine summary - Antipsychotics- chlorpromazine

Similar documents
MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia.

Medicine summary - Antipsychotics- haloperidol

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations.

Medicine summary - citalopram (to end January 2009)

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine

Database of Adverse Event Notifications - medicines

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Case Series Drug Analysis Print Name: Isotretinoin

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE

Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg UK/H/PSUR/0027/002 Date of FAR:

Database of Adverse Event Notifications - medicines

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:

Continence PGD - Oxybutynin 5mg Modified Release

M0BCore Safety Profile

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:

Nilotinib AEs (adverse events) in CML population:

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

Cetirizine Proposed Core Safety Profile

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1

Statin Adverse Reactions in the CARM database

Statin Adverse Reactions in the CARM database

PRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. Protein Kinase Inhibitor (L01XE23)

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care

GLUCOSE TESTING-BLOOD

4.4 Special warnings and precautions for use

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Buserelin Non European. European Economic Area

P-RMS: FR/H/PSUR/0036/001

0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:

UK Suspected Adverse Drug Reaction (ADR) Analysis

CSP Nabumetone ES/H/PSUR/0014/001. January 2010

Psychotherapeutic drugs

PROFESSIONAL INFORMATION

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C.

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DARZALEX. daratumumab. 20 mg/ml Concentrate for Solution for Infusion. Professed Standard

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

M0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR:

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)

Supplementary Online Content

1.1. An overview of reports on agomelatine

PRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. ATC Code: L01XE23 Protein Kinase Inhibitor

MYLAN-RIVASTIGMINE PATCH 5 Rivastigmine Transdermal Patch Each patch of 5 cm 2 contains 9 mg rivastigmine base, in vivo release rate of 4.6 mg/24 h.

Supplementary appendix

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.

1.1. An overview of reports on sitagliptin

TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM

RISPERIDONE Tablets, USP, for oral use. Initial U.S. Approval: 1993

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DARZALEX. daratumumab. 20 mg/ml Concentrate for Solution for Infusion. Professed Standard

RISPERDAL (risperidone)

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)

Pregabalin (Prepentin)

OXYSPAS Tablets (Oxybutynin chloride)

Supplementary materials for:

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

Supplementary Online Content

APPROVED PACKAGE INSERT

Sponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination

PRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets

PRODUCT MONOGRAPH. Pr MYOZYME. alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial. Enzyme Replacement Therapy

Headache Follow-up Visit Form

Package leaflet: Information for the user. LETROKS, 2,5 mg, film-coated tablets Letrozolum

Public Case Detail. Case Number : Reaction : Medicine details : Cases Count: 15. Gender : Weight (kg) : 36Y. Hospitalisation : Age :

PhUSE. PhUSE Computational Science Standard Analyses and Code Sharing Working Group

Each hard capsule contains 25 mg, 50 mg, 75 mg, 100 mg or 150 mg of pregabalin.

European PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

Core Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg

0BCore Safety Profile

Supplementary Online Content

Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride

Continence PGD transdermal oxybutynin Kentera patch 36mg

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -

Rytmonorm/Arythmol (propafenone) SR 225 mg, 325 mg, 425 mg Capsules and IR 10 mg, 150 mg, 300 mg Tablets and Intravenous Solution for Injection

Transcription:

591 21 241 Blood and lymphatic system disorders Anaemia 3 0 0 Aplastic anaemia 3 1 0 Pancytopenia 2 1 1 Thrombocytopenia 6 1 1 Thrombocytosis 1 0 0 Lymphadenopathy 3 1 1 Eosinophilia 5 0 0 Leukocytosis 4 0 1 Leukopenia 9 0 2 Lymphopenia 2 0 1 Agranulocytosis 14 3 3 Febrile neutropenia 1 0 1 Neutropenia 20 2 3 Blood and lymphatic system disorders 73 9 14 Cardiac disorders Bradycardia 1 0 0 Extrasystoles 2 0 0 Tachycardia 19 0 7 Sinus tachycardia 1 0 0 Supraventricular tachycardia 1 0 0 Cardiac arrest 1 0 0 Cardiac disorder 1 0 0 Cyanosis 2 0 0 Palpitations 4 0 2 Left ventricular failure 1 0 0 Right ventricular failure 1 0 0 Cardiomyopathy 1 0 0 Cardiomegaly 1 0 0 Ventricular dysfunction 1 0 0 Ventricular hypertrophy 1 0 0 Myocarditis 4 0 0 Cardiac disorders 42 0 9 Congenital, familial and genetic disorders Congenital foot malformation 1 0 0 22/07/2011-1 - 4:35:27 PM

Congenital, familial and genetic disorders Congenital, familial and genetic disorders 1 0 0 Ear and labyrinth disorders Ototoxicity 1 0 0 Deafness 3 0 0 Tinnitus 1 0 0 Ear and labyrinth disorders 5 0 0 Endocrine disorders Cushing's syndrome 1 0 0 Inappropriate antidiuretic hormone secretion 1 0 0 Hyperthyroidism 1 0 1 Hypothyroidism 1 0 0 Endocrine disorders 4 0 1 Eye disorders Cataract 3 0 0 Cataract subcapsular 2 0 0 Eye disorder 1 0 0 Eye pain 1 0 0 Lens disorder 1 0 1 Periorbital oedema 1 0 1 Glaucoma 1 0 0 Blepharitis 2 0 1 Blepharospasm 1 0 0 Oculogyric crisis 9 0 3 Miosis 1 0 1 Mydriasis 1 0 0 Retinal pigmentation 1 0 0 Visual acuity reduced 1 0 0 Vision blurred 1 0 1 Visual impairment 5 0 1 Eye disorders 32 0 9 Gastrointestinal disorders Pancreatitis 2 0 0 Gastrointestinal haemorrhage 1 0 0 Haematemesis 2 0 0 Melaena 1 0 0 Constipation 2 0 2 Megacolon 1 0 1 22/07/2011-2 - 4:35:27 PM

Gastrointestinal disorders Faeces discoloured 1 0 0 General disorders and administration site conditions Abdominal pain 6 0 3 Dysphagia 3 0 0 Faecal incontinence 1 0 0 Nausea 16 1 3 Vomiting 12 1 7 Cheilitis 2 0 1 Aphthous stomatitis 1 0 0 Mouth ulceration 2 0 0 Dry mouth 6 0 5 Salivary hypersecretion 5 0 0 Glossitis 1 0 1 Swollen tongue 1 0 1 Tongue oedema 7 0 5 Gastrointestinal disorders 73 2 29 Injection site inflammation 1 0 1 Injection site necrosis 1 0 1 Injection site reaction 6 0 5 Hypothermia 2 0 2 Hyperpyrexia 1 0 0 Pyrexia 26 2 3 1 1 0 Sudden death 5 5 0 Asthenia 1 0 0 Fatigue 4 1 0 Malaise 3 0 2 Gait disturbance 3 0 2 Condition aggravated 1 0 0 Influenza like illness 1 0 0 Irritability 2 0 1 Face oedema 12 0 8 Oedema 3 0 2 Oedema peripheral 5 0 4 22/07/2011-3 - 4:35:27 PM

General disorders and administration site conditions Chest pain 1 0 0 Pain 3 0 1 Chills 1 0 0 Feeling abnormal 1 0 0 Thirst 1 0 1 Drug ineffective 6 1 4 Paradoxical drug reaction 1 0 0 Drug withdrawal syndrome neonatal 1 0 0 General disorders and administration site conditions 93 10 37 Hepatobiliary disorders Hepatitis cholestatic 28 0 18 Jaundice 32 1 16 Jaundice cholestatic 1 0 0 Hepatic function abnormal 23 0 7 Hepatic failure 1 1 0 Hepatic cirrhosis 1 0 1 Hepatomegaly 2 0 1 Hepatitis 11 0 2 Hepatocellular injury 1 0 0 Hepatobiliary disorders 100 2 45 Immune system disorders Anaphylactoid reaction 1 0 1 Immune system disorders 1 0 1 Infections and infestations Cellulitis 2 0 2 Candidiasis 1 0 1 Abscess 1 0 1 Injection site abscess 3 0 2 Pneumonia 1 1 0 Sepsis 4 2 0 Rash pustular 4 0 3 Pharyngitis 4 1 2 Rhinitis 2 0 0 Upper respiratory tract infection 1 0 0 Infections and infestations 23 4 11 22/07/2011-4 - 4:35:27 PM

Injury, poisoning and procedural complications Toxicity to various agents 2 2 0 Drug exposure during pregnancy 2 0 0 Fall 3 0 1 Accidental overdose 1 1 0 Intentional overdose 1 0 0 Overdose 1 1 0 Injury, poisoning and procedural complications 10 4 1 Investigations Ejection fraction decreased 1 0 0 Electrocardiogram QT prolonged 2 0 0 Electrocardiogram abnormal 4 0 3 Blood pressure decreased 1 0 0 Blood thyroid stimulating hormone increased 1 0 1 Blood creatine phosphokinase increased 13 0 3 Troponin increased 1 0 0 Blood alkaline phosphatase increased 2 0 0 Prothrombin level decreased 2 0 0 Red blood cell sedimentation rate increased 2 0 0 Alanine aminotransferase increased 1 0 0 Gamma-glutamyltransferase increased 1 0 0 Hepatic enzyme increased 1 0 0 Liver function test abnormal 6 0 2 Oxygen saturation decreased 1 0 0 Weight decreased 1 0 1 Weight increased 3 0 2 Urine analysis abnormal 1 0 1 Investigations 44 0 13 Metabolism and nutrition disorders Ketosis 1 0 0 Decreased appetite 7 1 3 Obesity 1 0 0 Hypocalcaemia 1 0 0 Polydipsia 1 0 0 Hyperkalaemia 1 1 0 Hypokalaemia 3 0 0 22/07/2011-5 - 4:35:27 PM

Metabolism and nutrition disorders Hyponatraemia 10 1 2 Musculoskeletal and connective tissue disorders Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hyperglycaemia 2 1 0 Metabolism and nutrition disorders 27 4 5 Systemic lupus erythematosus 2 0 1 Arthralgia 2 0 0 Myalgia 2 0 0 Muscle twitching 5 0 1 Torticollis 2 0 1 Muscle necrosis 1 0 1 Rhabdomyolysis 3 0 1 Musculoskeletal stiffness 1 0 0 Back pain 1 0 1 Musculoskeletal and connective tissue disorders 19 0 6 Breast cancer female 1 0 0 Neoplasms benign, malignant and unspecified (incl cysts and polyps) 1 0 0 Nervous system disorders Cerebral haemorrhage 1 1 0 Tongue paralysis 2 0 0 Encephalopathy 2 0 0 Headache 6 0 2 Brain oedema 1 1 0 Amnesia 1 0 0 Disturbance in attention 2 0 2 Akathisia 3 0 0 Bradykinesia 1 0 0 Dyskinesia 9 0 2 Extrapyramidal disorder 19 0 4 Hyperkinesia 8 0 3 Hypokinesia 1 0 0 Tardive dyskinesia 11 0 5 Dystonia 28 0 8 Hemiparesis 1 0 1 Cogwheel rigidity 1 0 0 22/07/2011-6 - 4:35:27 PM

Nervous system disorders Parkinsonian gait 1 0 0 Tremor 14 0 5 Hyperreflexia 1 0 0 Ataxia 5 0 2 Coordination abnormal 1 0 1 Coma 4 0 3 Altered state of consciousness 1 0 0 Consciousness fluctuating 4 1 1 Depressed level of consciousness 2 0 1 Lethargy 1 0 1 Loss of consciousness 2 0 1 Sedation 2 0 1 Somnolence 18 0 8 Syncope 11 0 4 Dizziness 11 0 6 Dizziness postural 1 0 1 Unresponsive to stimuli 2 0 1 Hyperaesthesia 1 0 0 Paraesthesia 7 0 4 Dysgeusia 2 0 1 Hypoaesthesia 1 0 1 Sensory disturbance 1 0 0 Dysarthria 5 0 3 Speech disorder 2 0 1 Hypertonia 13 0 4 Neuroleptic malignant syndrome 20 1 4 Serotonin syndrome 3 1 0 Neuropathy peripheral 1 0 0 Convulsion neonatal 1 0 0 Grand mal convulsion 5 0 1 Convulsion 7 0 1 Nervous system disorders 247 5 83 22/07/2011-7 - 4:35:27 PM

Pregnancy, puerperium and perinatal conditions Intra-uterine death 1 1 1 Foetal growth restriction 2 0 0 Small for dates baby 1 0 0 Neonatal disorder 2 0 0 Pregnancy, puerperium and perinatal conditions 6 1 1 Psychiatric disorders Agitation 21 0 8 Anxiety 8 0 1 Nervousness 1 0 0 Fear 1 0 0 Catatonia 3 0 0 Restlessness 1 0 0 Confusional state 31 0 7 Disorientation 1 0 1 Delirium 5 0 0 Depression 3 0 0 Depersonalisation 1 0 1 Persecutory delusion 1 0 0 Hallucination 7 0 3 Hallucination, auditory 1 0 1 Thinking abnormal 3 0 1 Mania 1 0 0 Frustration 1 0 0 Aggression 2 0 1 Homicidal ideation 1 0 0 Personality change 1 0 0 Drug dependence 1 1 0 Withdrawal syndrome 1 0 0 Psychotic disorder 4 0 2 Libido decreased 1 0 0 Insomnia 3 0 1 Nightmare 3 0 2 Completed suicide 1 1 0 22/07/2011-8 - 4:35:27 PM

Psychiatric disorders Intentional self-injury 1 0 0 Self-injurious ideation 2 0 0 Suicidal ideation 2 0 0 Suicide attempt 5 0 1 Psychiatric disorders 118 2 30 Renal and urinary disorders Tubulointerstitial nephritis 1 1 0 Anuria 1 0 0 Renal failure acute 3 2 0 Renal impairment 5 1 0 Renal tubular necrosis 1 0 0 Dysuria 2 0 1 Urinary incontinence 4 0 1 Urinary retention 6 0 3 Choluria 1 0 1 Haematuria 3 0 1 Myoglobinuria 1 0 0 Renal and urinary disorders 28 4 7 Reproductive system and breast disorders Breast enlargement 1 0 1 Galactorrhoea 1 0 1 Erectile dysfunction 1 0 1 Priapism 6 0 3 Reproductive system and breast disorders 9 0 6 Respiratory, thoracic and mediastinal disorders Asthma 1 0 1 Wheezing 1 0 0 Pulmonary oedema 1 0 0 Pulmonary hypertension 1 0 0 Apnoea 2 0 2 Dyspnoea 10 1 5 Hyperventilation 1 0 0 Respiratory depression 3 2 0 Cough 1 0 0 Sputum increased 1 1 0 Dysphonia 1 0 0 22/07/2011-9 - 4:35:27 PM

Respiratory, thoracic and mediastinal disorders Oropharyngeal pain 1 0 0 Snoring 1 1 0 Throat tightness 3 0 1 Epistaxis 3 0 1 Sinus congestion 1 0 1 Respiratory, thoracic and mediastinal disorders 32 5 11 Skin and subcutaneous tissue disorders Angioedema 2 0 1 Urticaria 12 0 9 Blister 1 0 1 Dermatitis bullous 4 0 1 Erythema multiforme 1 0 0 Toxic epidermal necrolysis 2 1 0 Dry skin 1 0 1 Skin discolouration 3 0 2 Skin disorder 1 0 0 Skin necrosis 1 0 1 Skin swelling 1 0 1 Swelling face 1 0 1 Dermatitis 2 0 2 Dermatitis contact 3 0 3 Eczema 1 0 1 Seborrhoeic dermatitis 1 0 1 Erythema 1 0 1 Rash erythematous 10 0 3 Skin exfoliation 1 0 1 Rash papular 1 0 0 Photosensitivity reaction 20 0 10 Pruritus 40 0 20 Dermatitis psoriasiform 1 0 1 Rash 37 0 15 Rash macular 1 0 0 Rash maculo-papular 31 2 16 Rash morbilliform 3 0 1 22/07/2011-10 - 4:35:27 PM

Skin and subcutaneous tissue disorders Melanosis 1 0 1 Skin ulcer 3 0 0 Acne 1 0 1 Alopecia 1 0 0 Cold sweat 1 0 1 Hyperhidrosis 6 0 3 Seborrhoea 2 0 0 Purpura 5 1 1 Skin and subcutaneous tissue disorders 203 4 100 Social circumstances Verbal abuse 1 0 1 Immobile 1 0 0 Social circumstances 2 0 1 Vascular disorders Circulatory collapse 2 0 1 Hypotension 33 0 13 Orthostatic hypotension 13 0 6 Flushing 4 0 2 Pallor 4 0 2 Hypertension 4 0 2 Vascular disorders 60 0 26 1253 56 446 Rows are suppressed based on zeros and empty cells for 22/07/2011-11 - 4:35:27 PM